Genocea Biosciences Inc. (GNCA) Earns Outperform Rating from FBR & Co
A number of other research firms have also weighed in on GNCA. Piper Jaffray Cos. reduced their target price on Genocea Biosciences from $9.00 to $12.00 and set an overweight rating on the stock in a research note on Thursday, September 29th. Needham & Company LLC reiterated a buy rating and issued a $15.00 target price on shares of Genocea Biosciences in a research note on Thursday, September 29th. Finally, Zacks Investment Research lowered Genocea Biosciences from a hold rating to a sell rating in a research note on Wednesday, October 19th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. The company currently has an average rating of Buy and a consensus target price of $12.35.
Genocea Biosciences (NASDAQ:GNCA) opened at 4.3601 on Monday. The stock has a 50 day moving average price of $4.07 and a 200 day moving average price of $4.42. The stock’s market cap is $123.75 billion. Genocea Biosciences has a 52-week low of $2.56 and a 52-week high of $8.07.
Genocea Biosciences (NASDAQ:GNCA) last released its earnings results on Thursday, November 3rd. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by $0.01. Genocea Biosciences had a negative return on equity of 57.92% and a negative net margin of 5,121.17%. Analysts expect that Genocea Biosciences will post ($1.64) EPS for the current fiscal year.
A number of large investors have recently modified their holdings of GNCA. Northern Trust Corp increased its stake in shares of Genocea Biosciences by 24.3% in the third quarter. Northern Trust Corp now owns 34,636 shares of the company’s stock worth $177,000 after buying an additional 6,763 shares during the last quarter. AXA increased its stake in shares of Genocea Biosciences by 1.4% in the second quarter. AXA now owns 595,157 shares of the company’s stock worth $2,440,000 after buying an additional 8,183 shares during the last quarter. FMR LLC increased its stake in shares of Genocea Biosciences by 0.5% in the second quarter. FMR LLC now owns 4,244,037 shares of the company’s stock worth $17,401,000 after buying an additional 21,149 shares during the last quarter. Alpine Partners VI LLC bought a new stake in shares of Genocea Biosciences during the second quarter worth $120,000. Finally, TFS Capital LLC bought a new stake in shares of Genocea Biosciences during the second quarter worth $133,000. 58.65% of the stock is currently owned by institutional investors.
Genocea Biosciences Company Profile
Genocea Biosciences, Inc is a biopharmaceutical company. The Company discovers and develops vaccines and immunotherapies. It uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company operates through business of developing and commercializing vaccines segment.
Receive News & Stock Ratings for Genocea Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences Inc. and related stocks with our FREE daily email newsletter.